Placental, lipid, and glucidic effects of mammalian target of rapamycin inhibitors: Impact on fetal growth and metabolic disorders during pregnancy after solid organ transplantation

Mammalian target of rapamycin inhibitors (mTORi) are a promising new family of immunosuppressive drugs. No teratogenic effects have been reported to date. Their lipid and glucidic effects should not be underestimated, however, especially during pregnancy. Moreover, mTORi may affect fetal growth by mTOR placental activity.